The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•4 June 2026•

1 min read

Oculis Faces Legal Probe After Clinical Trial Failure Triggers 23% Stock Plunge

Key Facts

1Levi & Korsinsky announced an investigation into securities claims against Oculis Holding AG after the stock lost over 23% in a single session.

2Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet primary endpoints in diabetic macular edema.

3Oculis decided not to pursue an FDA filing for the OCS-01 indication following the trial failure.

Amid heightened volatility in the biotech sector, Levi & Korsinsky has announced an investigation into potential securities claims against Oculis Holding AG after the stock plummeted more than 23% in a single session. The sell-off followed the failure of Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01, which missed primary endpoints for treating diabetic macular edema. Consequently, Oculis has decided to abandon its plans for an FDA filing for this specific indication.

This clinical setback places Oculis under significant pressure compared to peers in the ophthalmology space; for instance, competitors like Kodiak Sciences have previously faced similar pipeline hurdles, underscoring the high-risk nature of retinal drug development. Per market data, shareholder rights law firms frequently initiate such probes following major clinical failures to determine if investors were misled regarding success probabilities, a common occurrence when stocks drop over 20%.

Investors should watch for stabilization levels in OCS following the heavy sell-off (close June 4, 2026). Looking ahead, broader healthcare sentiment may be influenced by upcoming macro catalysts, including speeches from Fed officials Kashkari and Schmid on May 29, 2026, which could impact funding environments for mid-cap biotech firms relying on capital markets.